Oxalate Simply Explained

1. What It Is About

Oxalate is the salt form of oxalic acid. It enters the body in two ways: via plant-based foods and via the body's own metabolism, that is the processes by which the body builds up and breaks down substances. It is formed mainly in the liver. In urine, oxalate is usually bound to calcium. That is why research almost always revolves around calcium oxalate crystals and the question of when stones form from them in the kidneys and urinary tract.

Oxalate is not a nutrient but an end product of metabolism. It has a narrow window: little is unremarkable, much becomes a risk. The studies distinguish several forms. In the congenital form, the body produces very large amounts of oxalate. In another form, it arises via the intestine. In a third, no clear cause is found. Gut bacteria also play a role: some can break down oxalate, yet how densely they colonise varies from person to person and does not remain constant.

Almost all studies measure oxalate in urine. That is a measured value. Whether a stone forms from it is another question.

2. What Studies Show

The best studied are agents that influence the oxalate content in urine or stone formation.

In a study with 53 adults with calcium or uric acid stones, the drug empagliflozin was tested. The participants received it for two weeks and then a placebo without active ingredient, or vice versa. The saturation of the urine with salts from which stones can form was measured. In participants with calcium stones, this saturation decreased for calcium phosphate; for calcium oxalate it did not change. In participants with uric acid stones, the saturation for uric acid decreased. No serious adverse effects occurred 4.

In the ILLUMINATE-A study, the drug lumasiran was tested in 39 people with the congenital form of excess oxalate, for up to 60 months. The amount of oxalate in urine remained low over the long observation period. The most common reports were mild reactions at the injection site 7.

A summary of several randomised studies tested thiazides, that is diuretic drugs, against a placebo in people with recurrent calcium stones and high calcium in urine. In such studies, chance decides who receives which treatment. 650 people were treated with them, 672 without them. New stones occurred less frequently under treatment. However, the individual studies were not uniform 1.

A further summary tested several drugs in calcium oxalate stones with abnormal urine values. New stones occurred less frequently; at the same time, more adverse effects occurred, which were predominantly mild 3.

In a study with 23 people who had been operated on for calcium oxalate stones, the participants took a mixture of lactic acid bacteria and mineral salts after discharge. After one month, no one had crystals in the urine any longer; after three months, likewise none of the 20 who were followed up. After six months, there were three participants; after twelve months, five 6.

A first investigation with four patients with the congenital form of excess oxalate tested a capsule with lanthanum carbonate that is released only in the lower intestine. The amount of oxalate in urine fell markedly below the value regarded as the upper limit 5.

In a randomised study with 72 people with recurrent calcium stones and elevated oxalate in urine, the amount of oxalate in urine fell in both groups, regardless of whether the participants received calcium citrate or took calcium via the diet. 28 participants did not complete the study 8.

A summary of five randomised studies with 208 patients with the congenital form of excess oxalate found no advantage in giving them the gut bacterium Oxalobacter formigenes: the oxalate values in blood and urine did not differ from those with a placebo 2.

3. What Remains Unclear

Most studies measure values in urine, not the event itself. A new stone takes time, and only some of the studies track it at all. Anyone who infers fewer stones from a lowered measured value turns a sign into an endpoint.

For empagliflozin, studies are still outstanding that actually count new stones and run over a longer period. Whether oxalate breakdown in the intestine really leads to fewer stones remains open. The lanthanum carbonate investigation comprised four patients; whether the effect is confirmed in larger groups needs to be clarified. In the congenital form of excess oxalate, administration of Oxalobacter formigenes in the summary brought no advantage over a placebo. Many findings on inflammation and cell damage come from cell cultures and animal experiments.

4. What This Means in Everyday Life

Anyone reading reports about oxalate can distinguish two things: measured values in urine and actual stone events. Only a few studies count stones over a long period.

Equally important is the separation of the forms. The congenital form with very high production is rare and is treated differently from ordinary stone formation. A good result in the rare form says nothing about the ordinary stone patient.

Small studies are indications, not proofs. They often show first that something is measurable and are the occasion for larger studies. What needs to be clarified next is whether lowered urine values translate into fewer new stones and whether the findings are confirmed in larger groups.

All details with study numbers and sources: detailed page on Oxalate. For children: Oxalate for Children.